Tie-2
Catalog No. | Inhibitor Name | Tie-2 | Other |
---|---|---|---|
A10996 | Cabozantinib | *** | VEGFR2/KDR,c-Met,Kit |
A10587 | MGCD-265 | **** | Met,RON,VEGFR2 |
A10932 | Tie2 kinase inhibitor | ** | |
A13456 | AMG-Tie2-1 | **** | |
A10895 | Pexmetinib (ARRY-614) | p38 MAPK | |
A14387 | Altiratinib (DCC2701) |
Notes:
1.Hover mouse over " " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
XL184 free base (Cabozantinib)
Catalog No. A10996 VEGFR 抑制剂XL184 free base (Cabozantinib)是设计用来抑制多种受体酪氨酸激酶(特别是MET和VEGFR2)的小分子。 了解更多 -
MGCD-265 (Glesatinib)
Catalog No. A10587 c-Met 抑制剂MGCD-265 (Glesatinib)是一种多靶酪氨酸激酶抑制剂,可与多种RTK(包括c-Met受体(HGFR)结合并抑制其磷酸化。Tek/Tie-2受体;VEGFR类型1、2和3;和MST1R。 了解更多 -
Tie2 kinase inhibitor
Catalog No. A10932 -
Altiratinib (DCC2701)
Catalog No. A14387 c-Met/VEGFR 抑制剂Altiratinib (DCC2701)是一种新型的c-MET/TIE-2/VEGFR抑制剂;与体外HGF拮抗剂相比,可有效降低体内的肿瘤负荷并阻断c-MET pTyr(1349)介导的信号传导,细胞生长和迁移。 了解更多 -
Pexmetinib (ARRY-614)
Catalog No. A10895 p38 MAPK 抑制剂Pexmetinib (ARRY-614)是通过双重抑制p38促分裂原活化蛋白激酶(MAPK)和Tie2/Tek受体酪氨酸激酶,其在HEK-293细胞中的IC50分别为4 nM/18 nM。Pexmetinib是一种有效的细胞因子合成抑制剂。 了解更多